Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Yantai Zhenghai Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Yantai Zhenghai Biotechnology şirketinin toplam hissedar öz sermayesi CN¥875.1M ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥960.0M ve CN¥84.9M dir. Yantai Zhenghai Biotechnology 'in FAVÖK'ü CN¥167.0M faiz karşılama oranı -11 dur. Şirketin CN¥588.6M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	-11x
Nakit	CN¥588.64m
Eşitlik	CN¥875.11m
Toplam yükümlülükler	CN¥84.88m
Toplam varlıklar	CN¥959.99m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Shares Not Telling The Full Story

Sep 28

Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) Held Back By Insufficient Growth Even After Shares Climb 26%

Mar 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 300653 'nin kısa vadeli varlıkları ( CN¥686.1M ) kısa vadeli yükümlülüklerini ( CN¥69.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 300653 şirketinin kısa vadeli varlıkları ( CN¥686.1M ) uzun vadeli yükümlülüklerini ( CN¥15.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 300653 borçsuzdur.

Borcun Azaltılması: 300653 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 300653 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 300653 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Yantai Zhenghai Biotechnology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New major risk - Share price stability

Yantai Zhenghai Biotechnology Co., Ltd. to Report Q3, 2024 Results on Oct 23, 2024

Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Shares Not Telling The Full Story

Investor sentiment improves as stock rises 16%

Now 22% overvalued

Now 20% overvalued

Investor sentiment deteriorates as stock falls 16%

New minor risk - Share price stability

Price target decreased by 7.6% to CN¥30.12

Second quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.31 in 2Q 2023)

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2024 Results on Aug 06, 2024

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2023, Payable on 14 June 2024

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.30 in 1Q 2023)

Price target decreased by 10% to CN¥31.34

Yantai Zhenghai Biotechnology Co., Ltd., Annual General Meeting, Apr 22, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Yantai Zhenghai Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Yantai Zhenghai Biotechnology Co., Ltd. (SZSE:300653) Held Back By Insufficient Growth Even After Shares Climb 26%

Investor sentiment deteriorates as stock falls 17%

Yantai Zhenghai Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 02, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.27 in 2Q 2022)

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2023 Results on Aug 01, 2023

Yantai Zhenghai Biotechnology Co., Ltd. Implements Final Cash Dividend of 10 A Shares for 2022, Payable on May 30, 2023

Investor sentiment deteriorates as stock falls 22%

Now 29% undervalued after recent price drop

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings released: EPS: CN¥1.01 (vs CN¥0.93 in FY 2021)

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.25 in 3Q 2021)

Investor sentiment improved over the past week

Now 26% undervalued after recent price drop

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.21 in 2Q 2021)

Investor sentiment improved over the past week

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Cash Dividend for the Year 2021, Payable on May 19, 2022

High number of new and inexperienced directors

First quarter 2022 earnings: EPS exceeds analyst expectations

Yantai Zhenghai Biotechnology Co., Ltd. Proposes Distribution for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.31 (vs CN¥0.30 in 2Q 2020)

Yantai Zhenghai Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 20, 2021

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.16 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.99 (vs CN¥0.89 in FY 2019)

New 90-day low: CN¥45.02

New 90-day low: CN¥49.35

New 90-day low: CN¥52.20

Investor sentiment deteriorated over the past week

New 90-day low: CN¥57.91

New 90-day low: CN¥61.00

Third quarter earnings released

New 90-day low: CN¥68.30

First half earnings released

Yantai Zhenghai Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 05, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin